Octagon Capital Advisors LP Viridian Therapeutics, Inc.\De Transaction History
Octagon Capital Advisors LP
- $639 Million
- Q1 2024
A detailed history of Octagon Capital Advisors LP transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Octagon Capital Advisors LP holds 620,000 shares of VRDN stock, worth $8.07 Million. This represents 1.7% of its overall portfolio holdings.
Number of Shares
620,000
Previous 620,000
-0.0%
Holding current value
$8.07 Million
Previous $13.5 Million
19.6%
% of portfolio
1.7%
Previous 2.25%
Shares
4 transactions
Others Institutions Holding VRDN
# of Institutions
143Shares Held
62.1MCall Options Held
160KPut Options Held
354K-
Paradigm Biocapital Advisors LP New York, NY5.03MShares$65.5 Million3.3% of portfolio
-
State Street Corp Boston, MA4.49MShares$58.4 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$50.5 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.81MShares$49.6 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.66MShares$47.6 Million1.34% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $519M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...